| Literature DB >> 27802302 |
Xing Liu1, Yongkai Ye2, Qi Mi3, Wei Huang1, Ting He1, Pin Huang1, Nana Xu4, Qiaoyu Wu1, Anli Wang5, Ying Li1,4, Hong Yuan1,4.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a serious post-surgery complication; however, few preoperative risk models for AKI have been developed for hypertensive patients undergoing general surgery. Thus, in this study involving a large Chinese cohort, we developed and validated a risk model for surgery-related AKI using preoperative risk factors. METHODS ANDEntities:
Mesh:
Substances:
Year: 2016 PMID: 27802302 PMCID: PMC5089779 DOI: 10.1371/journal.pone.0165280
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline Characteristics of Subjects in the Training and Validation Cohorts.
| Total Cohort (n = 24451) | Training Cohort (n = 17020) | Validation Cohort (n = 7362) | |
|---|---|---|---|
| Age (years) | 57.95±13.98 | 57.92±13.97 | 58.03±14.00 |
| Male sex (%) | 50.5 | 50.5 | 50.6 |
| BMI (kg/m2) | 24.27±3.25 | 24.25±3.23 | 24.31±3.29 |
| SBP (mmHg) | 137.95±19.70 | 138.00±19.61 | 137.81±19.91 |
| DBP (mmHg) | 80.88±12.22 | 80.94±12.13 | 80.75±12.44 |
| Duration of hypertension (years) | 8.17±7.77 | 8.03±7.71 | 8.46±7.90 |
| Current smoker (%) | 20.9 | 21.0 | 20.6 |
| Alcohol consumption (%) | 12.5 | 12.5 | 12.6 |
| eGFR | 77.80±32.28 | 77.66±32.33 | 77.97±32.30 |
| Diagnoses | |||
| CKD (%) | 23 | 23 | 22.8 |
| Diabetes mellitus (%) | 20.4 | 20.6 | 20.0 |
| Heart failure (%) | 12.0 | 12.1 | 11.9 |
| Virus hepatitis (%) | 3.5 | 3.5 | 3.6 |
| Pulmonary infection (%) | 10.4 | 10.3 | 10.6 |
| Respiratory failure (%) | 0.6 | 0.6 | 0.7 |
| COPD (%) | 2.0 | 2.0 | 2.0 |
| Peripheral vascular disease (%) | 2.6 | 2.5 | 2.7 |
| History of disease | |||
| Cancer | 7.8 | 7.9 | 7.5 |
| Acute coronary syndrome | 4.6 | 4.7 | 4.4 |
| Acute cerebrovascular events | 7.8 | 7.9 | 7.4 |
| Drug use | |||
| Insulin (%) | 11.1 | 11.1 | 10.9 |
| Oral anti-diabetic drugs (%) | 5.6 | 5.5 | 5.7 |
| Contrast medium (%) | 1.8 | 1.8 | 1.6 |
| Vasodilator (%) | 23.5 | 23.4 | 23.7 |
| Antiplatelet or anticoagulant (%) | 37.1 | 36.9 | 37.6 |
| Lipid-regulating drugs (%) | 15.4 | 15.4 | 15.5 |
| Cardiotonic drugs (%) | 0.4 | 0.4 | 0.4 |
| Anti-arrhythmic drugs (%) | 1.1 | 1.0 | 1.3 |
| Anti-shock drugs (%) | 5.0 | 4.8 | 5.3 |
| Laboratory examinations | |||
| Neutrophils ( | 5.70±4.06 | 5.68±3.75 | 5.75±4.69 |
| Lymphocytes ( | 1.59±0.95 | 1.59±0.70 | 1.59±1.36 |
| NLR | 4.53±4.40 | 4.51±4.41 | 4.58±4.38 |
| Eosinophils ( | 0.14±0.17 | 0.14±0.17 | 0.14±0.19 |
| Basophils ( | 0.02±0.10 | 0.02±0.10 | 0.02±0.10 |
| Red blood cells ( | 4.12±0.78 | 4.12±0.78 | 4.13±0.78 |
| Hemoglobin (g/L) | 121.54±23.65 | 121.35±23.70 | 121.96±23.53 |
| Blood platelets ( | 194.78±71.14 | 195.58±71.80 | 192.92±69.54 |
| Glucose (mmol/L) | 5.76±2.23 | 5.77±2.29 | 5.74±2.09 |
| ALT (u/L) | 29.43±74.91 | 29.53±83.25 | 29.20±50.33 |
| AST (u/L) | 32.23±91.18 | 32.46±103.15 | 31.68±83.25 |
| Serum total protein (g/L) | 66.31±7.65 | 66.29±7.66 | 66.36±7.62 |
| Serum albumin (g/L) | 39.37±5.31 | 39.37±5.31 | 39.40±5.27 |
| Serum globulin (g/L) | 26.94±4.85 | 26.93±4.88 | 26.96±4.77 |
| Total cholesterol (mmol/L) | 4.67±1.20 | 4.67±1.20 | 4.69±1.89 |
| LDL (mmol/L) | 2.58±0.89 | 2.60±0.89 | 2.57±0.90 |
| HDL (mmol/L) | 0.79±0.23 | 0.79±0.23 | 0.79±0.24 |
| Uric acid (μmol/L) | 321.25±111.90 | 321.05±112.05 | 321.71±111.33 |
| BUN (mmol/L) | 7.16±5.90 | 7.14±5.87 | 7.19±5.97 |
| TT (s) | 15.76±7.85 | 15.75±7.69 | 15.79±8.23 |
| PT (s) | 11.80±3.00 | 11.80±3.17 | 11.79±2.56 |
| INR | 1.01±0.20 | 1.01±0.20 | 1.01±0.20 |
| Serum potassium (mmol/L) | 4.07±0.48 | 4.07±0.48 | 4.07±0.49 |
| Serum sodium (mmol/L) | 140.37±3.08 | 140.36±3.07 | 140.39±3.10 |
| Serum chlorine (mmol/L) | 104.39±3.76 | 104.38±3.78 | 104.42±3.10 |
| Serum calcium (mmol/L) | 2.26±0.18 | 2.26±0.18 | 2.26±0.18 |
| CO2CP (mmol/l) | 23.92±3.73 | 23.91±3.73 | 23.95±3.74 |
| Anion gap (mmol/l) | 16.42±3.97 | 16.42±3.94 | 16.41±4.04 |
| Urine pH | 6.23±0.71 | 6.23±0.71 | 6.23±0.72 |
| Urine specific gravity | 1.02±0.07 | 1.02±0.01 | 1.02±0.01 |
| Surgical sites | |||
| EENT surgery (%) | 9.5 | 9.4 | 9.6 |
| Blood and lymphatic system surgery (%) | 1.6 | 1.6 | 1.6 |
| Cardiovascular surgery (%) | 12.8 | 12.7 | 13.0 |
| Digestive surgery (%) | 19.8 | 20.0 | 19.3 |
| Integumentary system surgery (%) | 3.1 | 3.0 | 3.2 |
| Nervous system surgery (%) | 4.3 | 4.0 | 4.9 |
| Urogenital surgery (%) | 26.1 | 26.1 | 25.9 |
| Endocrine surgery (%) | 2.7 | 2.7 | 2.7 |
| Musculoskeletal surgery (%) | 6.5 | 6.4 | 6.6 |
| Respiratory surgery (%) | 3.2 | 3.3 | 3.1 |
| Other sites (%) | 10.6 | 10.9 | 10.2 |
Data are numbers (percentage) and mean ± standard deviation. ALT, glutamic oxaloacetic transaminase; AST, aspartate amino transferase; BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; CO2CP, carbon dioxide combining power; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; EENT, ear, eye, nose and throat surgery; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein cholesterol; INR, International Normalized Ratio; LDL, low-density lipoprotein cholesterol; NLR, neutrophil-to-lymphocyte ratio; PT, prothrombin time; PVD, peripheral vascular disease; SBP, systolic blood pressure, TT, thrombin time.
*For the difference between patients in the Training Cohort and patients in the Validation Cohort, P value<0.05.
Xiany-ya Risk Model Calculation Formula.
| Variables | Coefficient |
|---|---|
| eGFR | -0.034 |
| NLR | 0.067 |
| TT | 0.015 |
| Serum potassium | 0.259 |
| Pulmonary infection (1 if present) | 0.514 |
| Age | -0.016 |
| Uric acid | -0.002 |
| Serum albumin | -0.020 |
| AST | 0.002 |
| Total cholesterol | 0.071 |
| Gender (1 if male, 2 if female) | -0.314 |
| PT | 0.021 |
| Hemoglobin | -0.006 |
The probability of significant surgery-associated AKI was calculated as
1/(1 + e−)
where e = base of the natural logarithm, where x = ay+ay+…+ay+B, where y1, y2, …, yk are the characteristics, where a1, a2, …, ak are the corresponding logistic regression coefficients, and where B is the intercept term (in this case, 0.694).
The predictive characteristics are listed here with their coefficients.
AST, aspartate amino transferase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; PT, prothrombin time; TT, thrombin time
Fig 1Receiver Operating Characteristic Curves for the Xiang-ya Model of Surgery-related AKI in the Training and Validation Sets (A) and in the Training and Cross-Validation Set (B).
AUC, area under the receiver operating characteristic curve.
Diagnostic and Predictive Values of the Xiang-ya Risk Model at Different Cutoff Points for Predicted Probability.
| Cutoff point for predicted probability | Sensitivity | Specificity | Positive predictive value | Negative predicted value | Youden index | Gmean |
|---|---|---|---|---|---|---|
| 0.05 | 0.87 | 0.77 | 0.26 | 0.98 | 0.64 | 0.82 |
| 0.06 | 0.85 | 0.81 | 0.29 | 0.98 | 0.66 | 0.83 |
| 0.07 | 0.82 | 0.83 | 0.31 | 0.98 | 0.65 | 0.83 |
| 0.08 | 0.8 | 0.85 | 0.32 | 0.98 | 0.65 | 0.83 |
| 0.09 | 0.79 | 0.86 | 0.34 | 0.98 | 0.65 | 0.83 |
| 0.10 | 0.77 | 0.87 | 0.36 | 0.98 | 0.64 | 0.82 |
| 0.15 | 0.71 | 0.9 | 0.4 | 0.97 | 0.61 | 0.8 |
| 0.20 | 0.67 | 0.92 | 0.43 | 0.97 | 0.59 | 0.78 |
| 0.30 | 0.56 | 0.94 | 0.47 | 0.96 | 0.51 | 0.73 |
Fig 2Flow Chart of Eligible Studies for Model Comparison.
Fig 3Comparison of the Receiver Operating Characteristic Curves for the Xiang-ya Model and the Model Proposed by Kate et al 2014 for Predicting Cardiac Surgery-related AKI (n = 2101).
AUC, area under the receiver operating characteristic curve.